ABOS Stock Summary and Trading Ideas (Acumen Pharmaceuticals | NASDAQ:ABOS)

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Acumen Pharmaceuticals trades on the NASDAQ stock market under the symbol ABOS.

As of January 16, 2026, ABOS stock price climbed to $1.89 with 305,238 million shares trading.

ABOS has a beta of 1.93, meaning it tends to be more sensitive to market movements. ABOS has a correlation of 0.19 to the broad based SPY ETF.

ABOS has a market cap of $114.48 million. This is considered a Micro Cap stock.

In the last 3 years, ABOS traded as high as $11.31 and as low as $.86.

The top ETF exchange traded funds that ABOS belongs to (by Net Assets): VTI, VXF, IWC, DFAC, AVSC.

ABOS has underperformed the market in the last year with a price return of +17.4% while the SPY ETF gained +18.1%. ABOS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.3% and -6.4%, respectively, while the SPY returned +5.0% and +1.2%, respectively.

ABOS support price is $1.77 and resistance is $1.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABOS shares will trade within this expected range on the day.